Provided by Tiger Trade Technology Pte. Ltd.

Goldman Sachs Future Health Care Equity ETF

36.52
0.0000
Volume:10
Turnover:365.43
Market Cap:19.17M
PE:- -
High:36.52
Open:36.52
Low:36.52
Close:36.52
52wk High:38.66
52wk Low:31.32
Shares:525.00K
Float Shares:525.00K
Volume Ratio:0.02
T/O Rate:0.00%
Dividend:0.11
Dividend Rate:0.31%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Eli Lilly: Breaks Ground on Fifth U.S. API Manufacturing Site in Houston

THOMSON REUTERS
·
Sep 22

Eli Lilly: Houston Facility to Manufacture Active Pharmaceutical Ingredients for Medicines Like Foundayo

THOMSON REUTERS
·
Sep 22

Biogen Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 22

Estee Lauder Cos. Cl a Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 22

Sector Update: Healthcare

MT Newswires Live
·
Sep 22

Nvidia Corp., Merck Share Gains Lead Dow's 425-Point Climb

Dow Jones
·
Sep 22

Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients taking Foundayo

TIPRANKS
·
Sep 22

Top Midday Stories: Paramount Skydance Settles With US States to Pave Way for Warner Bros. Deal; Anthropic Now Eyeing November IPO

MT Newswires Live
·
Sep 21

Novo Nordisk Says New Obesity Drug Outperformed Lilly's Zepbound in Phase 3 Trial

Dow Jones
·
Sep 21

J&J says Caplyta Phase 3 study in bipolar I met primary endpoint

TIPRANKS
·
Sep 21

Novo Stock (NVO) Sinks Despite Beating Eli Lilly in New CagriSema Obesity Trial

TIPRANKS
·
Sep 21

Avalyn Pharma announces published results from Phase 1 trials of AP02

TIPRANKS
·
Sep 21

InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million

GlobeNewswire
·
Sep 21

Johnson & Johnson Says Phase 3 Trial Shows Caplyta Cuts Bipolar I Mania Symptoms by Week 3

Reuters
·
Sep 21

J&J - Caplyta Demonstrates Statistically Significant Rapid Reduction in Manic Symptoms at Week 3

THOMSON REUTERS
·
Sep 21

Caplyta® (Lumateperone) Shows Significant and Rapid Improvement in Bipolar Mania in Pivotal Phase 3 Study

THOMSON REUTERS
·
Sep 21

J&J - Caplyta Well-Tolerated; Dry Mouth and Nausea Most Common Adverse Events

THOMSON REUTERS
·
Sep 21

Oura Files for Initial Public Offering on Nasdaq

MT Newswires Live
·
Sep 21

LIVE Markets-Big Beauty Faces Growing Threat from AI, Smaller Rivals

Reuters
·
Sep 21

Smart Ring Maker Oura Eyes $15.6 Billion IPO Valuation in Fall Listings Demand Test

Reuters
·
Sep 21